The present study demonstrated that the use of lapatinib in a feline with advanced GIST positive for EGFR1 and HER-2 resulted in a partial response to liver metastasis, with a PFS of 171 days and an OS of 192 days after starting lapatinib. The gene discussed is ERBB2; the disease is gastrointestinal stromal tumor.